Chronic hepatitis B (CHB)
Conditions
Interventions
Nucleotide analog group:Nucleoside analogue antiviral therapy
No antiviral group:No antiviral treatment
Normal group:Nil
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with hepatitis B surface antigen (HBsAg) lasting more than 6 months; 2. Aged from 18 to 65 years; 3. Willingness to receive nucleoside analogue antiviral treatment for the first time; 4. Signing a written informed consent for the research content and laboratory testing items of this project, and willing to participate in a 5-year follow-up survey.
Exclusion criteria
Exclusion criteria: 1. Patients with severe mental and neurological diseases; 2. People who are mentally handicapped or unable to communicate effectively with researchers; 3. Patients with combined alcohol, metabolism, and autoimmune liver disease. 4. Patients receiving interferon antiviral therapy. 5. Decompensated liver cirrhosis or hepatocellular carcinoma (HCC). 6. Pregnant or lactating women. 7. Patients with severe underlying diseases and immunodeficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRP4; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBV DNA;HBsAg, HBsAb, HBeAg, HBeAb, HBcAb; | — |
Countries
China
Contacts
Public ContactZheng Xin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed